For research use only. Not for therapeutic Use.
JUN-1111 is an irreversible and selective Cdc25 phosphatase inhibitor with IC50 values of 0.38, 1.8, 0.66, 28, 37 µM for Cdc25A, Cdc25B, Cdc25C, VHR, PTP1B, respectively. JUN-1111 induces cell cycle arrest at G1 and G2/M phases. JUN-1111 decreases the expression of phosphoCdk1[1][2].
JUN-1111 (10, 30 µM; 17 h) induces cell cycle arrest at G1 and G2/M phase in tsFT210 cells[1].
JUN-1111 (10, 30 µM; 1 h) decreases the expression of phosphoCdk1 in a dose-dependent manner in tsFT210 cells[1].
JUN-1111 (0-20 µM) induces the formation of reactive oxygen species in mammalian cells[2].
| Catalog Number | I029896 |
| CAS Number | 874351-38-9 |
| Synonyms | 7-(2-morpholin-4-ylethylamino)quinoline-5,8-dione |
| Molecular Formula | C15H17N3O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C15H17N3O3/c19-13-10-12(15(20)14-11(13)2-1-3-17-14)16-4-5-18-6-8-21-9-7-18/h1-3,10,16H,4-9H2 |
| InChIKey | QWIRJCMQNFHGJV-UHFFFAOYSA-N |
| SMILES | C1COCCN1CCNC2=CC(=O)C3=C(C2=O)N=CC=C3 |
| Reference | [1]. Brisson M, et al. Redox regulation of Cdc25B by cell-active quinolinediones. Mol Pharmacol. 2005 Dec;68(6):1810-20. [2]. Vogt A, et al. A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells. Mol Cancer Ther. 2008 Feb;7(2):330-40. |
